Glimilife-M3 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 3 mg and Metformin 500 mg in a sustained-release formulation. It is indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled by diet and exercise alone or those requiring combination therapy. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, facilitating better glucose uptake by tissues. The sustained-release formulation ensures a gradual release of active ingredients, promoting improved glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. Glimilife-M3 aids in achieving target blood glucose levels, minimizing the risk of hyperglycemia and its associated complications. It is recommended to be taken once daily with meals to enhance absorption and minimize adverse effects. Regular monitoring of blood glucose, renal function, and hepatic parameters is advised during therapy. Caution is warranted in patients with renal impairment, hepatic dysfunction, or cardiac conditions. Glimilife-M3 should be used under medical supervision, with appropriate lifestyle modifications including diet and exercise for optimal diabetes management.